Women's perceptions on medical abortion

Contraception

Volumn 74, Issue 1, 2006, Pages 11-15

  Ho, Pak Chung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Medical abortion; Perceptions

Indexed keywords

ABORTIVE AGENT; METHOTREXATE; MIFEPRISTONE; MISOPROSTOL;

ABORTION; BLEEDING; GESTATIONAL AGE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PAIN; PERCEPTION; PREGNANCY TERMINATION; QUESTIONNAIRE; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; UNITED STATES;

ABORTION, INDUCED; FEMALE; GESTATIONAL AGE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PATIENT SATISFACTION; PERCEPTION; PREGNANCY;

EID: 33745028165     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.02.012     Document Type: Review

References (23)

1. Tang G.W.K. A pilot study of acceptability of RU486 and ONO 802 in a Chinese population. Contraception 44 (1991) 523-532
2. Tang G.W.K., Lau O.W.K., and Yip P. Further acceptability evaluation of RU486 and ONO 802 as abortifacient agents in a Chinese population. Contraception 48 (1993) 267-276
3. Henshaw R.C., Naji S.A., Russell I.T., et al. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. BMJ 307 (1993) 714-717
4. Wiebe E.R. Choosing between surgical abortions and medical abortions induced with methotrexate and misoprostol. Contraception 55 (1997) 67-71
5. Winikoff B, Sivin I, Coyaji KJ, et al. The acceptability of medical abortion in China, Cuba and India. Int Fam Plann Perspect 1997;23:73-78, 89.
6. Beckman L.J., and Harvey S.M. Experience and acceptability of medical abortion with mifepristone and misoprostol among U.S. women. Wom Health 7 (1997) 253-262
7. Honkanen H., and von Hertzen H. Users' perspectives on medical abortion in Finland. Contraception 65 (2002) 419-423
8. Coyaji K., Elul B., Krishna U., et al. Mifepristone-misoprostol abortion: a trial in rural and urban Maharashtra, India. Contraception 66 (2002) 33-40
9. 1 analog vaginal pessary for the termination of early pregnancy: complications and patient acceptability. Am J Obstet Gynecol 162 (1990) 414-417
10. Urquhart D.R., and Templeton A.A. Psychiatric morbidity and acceptability following medical and surgical methods of induced abortion. BJOG 98 (1991) 396-399
11. Thong K.J., Dewar M.H., and Baird D.T. What do women want during medical abortion?. Contraception 46 (1992) 435-442
12. Winikoff B., Ellertson C., Elul B., et al. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol. Arch Fam Med 7 (1998) 360-366
13. Slade P., Heke S., Fletcher J., et al. A comparison of medical and surgical termination of pregnancy: choice, emotional impact and satisfaction with care. BJOG 105 (1998) 1288-1295
14. Bjørge L., Johnsen S.L., Midbøe G., et al. Early pregnancy termination with mifepristone and misoprostol in Norway. Acta Obstet Gynecol Scand 80 (2001) 1056-1061
15. Jensen J.T., Harvey S.M., and Beckman L.J. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study. Am J Obstet Gynecol 182 (2000) 1292-1299
16. Phelps R.H., Schaff E.A., and Fielding S.L. Mifepristone abortion in minors. Contraception 64 (2001) 339-343
17. Knudsen U.B. First trimester abortion with mifepristone and vaginal misoprostol. Contraception 63 (2001) 247-250
18. Honkanen H., Piaggio G., von Hertzen H., et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion: II. Side effects and women's perceptions. BJOG 111 (2004) 1-11
19. Creinin M.D. Randomized comparison of efficacy, acceptability and cost of medical versus surgical abortion. Contraception 62 (2000) 117-124
20. Schaff E.A., Stadalius L.S., Eisinger S.H., et al. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. J Fam Pract 44 (1997) 353-360
21. Schaff E.A., Eisinger S.H., Stadalius L.S., et al. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception 59 (1999) 1-6
22. Schaff E.A., Fielding S.L., Eisinger S.H., et al. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception 61 (2000) 41-46
23. Ngoc N.T.N., Nhan V.Q., Blum J., et al. Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from a multisite study in Vietnam. BJOG 111 (2004) 814-819